Abstract
Sudoxicam strongly inhibited aggregation of rabbit, dog and human platelets caused by collagen, but not by adenosine diphosphate (ADP). In human plasma, sudoxicam was more potent than aspirin. Sudoxicam inhibited the secondary phase of the biphasic response of guinea-pig platelets to ADP and suppressed release of ADP from human platelets caused by collagen. After oral administration to dogs of a single dose of sudoxicam, 1 mg/kg, impaired platelet responses to collagen were observed for 96 to 120 hours and were associated with plasma drug levels of less than 0.5 γg/ml; there was no effect on whole blood platelet count. In dogs, thrombus formation in the inverted artery model of thrombosis was diminished after intravenous injection of sudoxicam, 1 mg/kg. After oral administration to humans of a single dose of 50 mg of sudoxicam, platelet inhibitory activity was observed for at least 24 hours and was associated with plasma drug concentration of approximately 3 µg/ml. Administration of 50 mg of sudoxicam on each of three consecutive days was sufficient to elevate plasma concentration beyond this level, and 20 mg on each of two successive days sustained it; platelet responses returned to predrug levels 48 to 144 hours after treatment was terminated. There was no effect on whole blood platelet count.
Footnotes
- Received April 20, 1973.
- Accepted July 20, 1973.
- © 1973 by The Williams & Wilkins Co.
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|